Feng Wang is currently a Drug Discovery Scientist in Vanderbilt University. He works on the discovery of novel anticancer drugs that target epigenetic factors and immune checkpoint proteins using fragment-based approach and structure-based design. Dr. Wang obtained his B.Sc. in basic science from Tsinghua University, and Ph.D. in medical biophysics from Ontario Cancer Institute University of Toronto. Dr. Wang also serves as the peer-reviewer for many Sci-indexed scientific journals, including J Mol Biol, Plos one, J Theor Biol, and Onco Targets and therapy.